Limits...
Operable breast cancer of the inner hemisphere is associated with poor survival.

Xue C, Peng RJ, Wang SS, Shi YX, An X, Xu F, Yuan ZY - J Breast Cancer (2015)

Bottom Line: The association between tumor location and the 5-year DFS rate was most apparent in node-positive patients (73.1% vs. 65.8% for outer vs. inner hemisphere lesions, p<0.001) and in patients with primary tumors greater than 2 cm in diameter (78.2% vs. 72.3%, p=0.002).Multivariate analysis showed that tumor location was an independent predictor of DFS (hazard ratio [HR], 1.23; p=0.002) and OS (HR, 1.28; p=0.006).There were no significant differences in 5-year DFS or OS rates between patients with outer versus inner hemisphere tumors when internal mammary node irradiation was performed.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.

ABSTRACT

Purpose: This study investigated the clinicopathological features of operable breast cancer lesions located in different hemispheres of the breast and determined related survival outcomes.

Methods: Data from 5,330 patients with invasive ductal carcinoma were retrospectively analyzed based on tumor location.

Results: The median follow-up time was 68 months (range, 18-176 months). Patients with breast cancer located in the outer hemisphere of the breast had lesions with more advanced nodal stages and more frequently received adjuvant chemotherapy than patients with breast cancer in the inner hemisphere. The 5-year disease-free survival (DFS) rates of patients with tumors located in outer versus inner hemispheres were 81.5% and 77.0%, respectively (p=0.004); the overall survival (OS) rates were 90.7% and 88.8%, respectively (p<0.001). The association between tumor location and the 5-year DFS rate was most apparent in node-positive patients (73.1% vs. 65.8% for outer vs. inner hemisphere lesions, p<0.001) and in patients with primary tumors greater than 2 cm in diameter (78.2% vs. 72.3%, p=0.002). Multivariate analysis showed that tumor location was an independent predictor of DFS (hazard ratio [HR], 1.23; p=0.002) and OS (HR, 1.28; p=0.006). There were no significant differences in 5-year DFS or OS rates between patients with outer versus inner hemisphere tumors when internal mammary node irradiation was performed.

Conclusion: This study demonstrated that tumor location was an independent prognostic factor for operable breast cancer. Internal mammary node irradiation is recommended for patients with breast cancer of the inner hemisphere and positive axillary lymph nodes or large primary tumors.

No MeSH data available.


Related in: MedlinePlus

Five-year disease-free survival (DFS) and overall survival (OS) rates for patients who were lymph node positive (n=2,653) or had tumors larger than 2 cm in diameter (n=3,687) by location of breast cancer in different hemispheres. (A) The 5-year DFS for patients who were lymph node positive. (B) The 5-year OS for patients who were lymph node positive. (C) The 5-year DFS for patients who had tumors larger than 2 cm in diameter. (D) The 5-year OS for patients who had tumors larger than 2 cm in diameter.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4381121&req=5

Figure 2: Five-year disease-free survival (DFS) and overall survival (OS) rates for patients who were lymph node positive (n=2,653) or had tumors larger than 2 cm in diameter (n=3,687) by location of breast cancer in different hemispheres. (A) The 5-year DFS for patients who were lymph node positive. (B) The 5-year OS for patients who were lymph node positive. (C) The 5-year DFS for patients who had tumors larger than 2 cm in diameter. (D) The 5-year OS for patients who had tumors larger than 2 cm in diameter.

Mentions: Patients were further categorized by traditional prognostic factors, including age (younger or older than 35 years), lymph node status (negative or positive), tumor size (smaller or larger than 2 cm in diameter), ER/PR status (negative or positive), HER2 status (negative or positive), and LVI status (present or absent). The 5-year DFS and OS rates were not significantly different between patients with breast cancer of the outer versus inner hemisphere, except for patients with positive lymph nodes or tumors lager than 2 cm in diameter. Among the patients with positive lymph nodes, the 5-year DFS rates for patients with breast cancer of the outer and inner hemisphere were 73.1% and 65.8%, respectively (p<0.001); the 5-year OS rates were 86.3% and 83.0%, respectively (p=0.001) (Figure 2A, B). Among the patients with tumors larger than 2 cm in diameter, the 5-year DFS rates for patients with breast cancer of the outer and inner hemisphere were 78.2% and 72.3%, respectively (p=0.002); their OS rates were 89.0% and 86.3%, respectively (p<0.001) (Figure 2C, D).


Operable breast cancer of the inner hemisphere is associated with poor survival.

Xue C, Peng RJ, Wang SS, Shi YX, An X, Xu F, Yuan ZY - J Breast Cancer (2015)

Five-year disease-free survival (DFS) and overall survival (OS) rates for patients who were lymph node positive (n=2,653) or had tumors larger than 2 cm in diameter (n=3,687) by location of breast cancer in different hemispheres. (A) The 5-year DFS for patients who were lymph node positive. (B) The 5-year OS for patients who were lymph node positive. (C) The 5-year DFS for patients who had tumors larger than 2 cm in diameter. (D) The 5-year OS for patients who had tumors larger than 2 cm in diameter.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4381121&req=5

Figure 2: Five-year disease-free survival (DFS) and overall survival (OS) rates for patients who were lymph node positive (n=2,653) or had tumors larger than 2 cm in diameter (n=3,687) by location of breast cancer in different hemispheres. (A) The 5-year DFS for patients who were lymph node positive. (B) The 5-year OS for patients who were lymph node positive. (C) The 5-year DFS for patients who had tumors larger than 2 cm in diameter. (D) The 5-year OS for patients who had tumors larger than 2 cm in diameter.
Mentions: Patients were further categorized by traditional prognostic factors, including age (younger or older than 35 years), lymph node status (negative or positive), tumor size (smaller or larger than 2 cm in diameter), ER/PR status (negative or positive), HER2 status (negative or positive), and LVI status (present or absent). The 5-year DFS and OS rates were not significantly different between patients with breast cancer of the outer versus inner hemisphere, except for patients with positive lymph nodes or tumors lager than 2 cm in diameter. Among the patients with positive lymph nodes, the 5-year DFS rates for patients with breast cancer of the outer and inner hemisphere were 73.1% and 65.8%, respectively (p<0.001); the 5-year OS rates were 86.3% and 83.0%, respectively (p=0.001) (Figure 2A, B). Among the patients with tumors larger than 2 cm in diameter, the 5-year DFS rates for patients with breast cancer of the outer and inner hemisphere were 78.2% and 72.3%, respectively (p=0.002); their OS rates were 89.0% and 86.3%, respectively (p<0.001) (Figure 2C, D).

Bottom Line: The association between tumor location and the 5-year DFS rate was most apparent in node-positive patients (73.1% vs. 65.8% for outer vs. inner hemisphere lesions, p<0.001) and in patients with primary tumors greater than 2 cm in diameter (78.2% vs. 72.3%, p=0.002).Multivariate analysis showed that tumor location was an independent predictor of DFS (hazard ratio [HR], 1.23; p=0.002) and OS (HR, 1.28; p=0.006).There were no significant differences in 5-year DFS or OS rates between patients with outer versus inner hemisphere tumors when internal mammary node irradiation was performed.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.

ABSTRACT

Purpose: This study investigated the clinicopathological features of operable breast cancer lesions located in different hemispheres of the breast and determined related survival outcomes.

Methods: Data from 5,330 patients with invasive ductal carcinoma were retrospectively analyzed based on tumor location.

Results: The median follow-up time was 68 months (range, 18-176 months). Patients with breast cancer located in the outer hemisphere of the breast had lesions with more advanced nodal stages and more frequently received adjuvant chemotherapy than patients with breast cancer in the inner hemisphere. The 5-year disease-free survival (DFS) rates of patients with tumors located in outer versus inner hemispheres were 81.5% and 77.0%, respectively (p=0.004); the overall survival (OS) rates were 90.7% and 88.8%, respectively (p<0.001). The association between tumor location and the 5-year DFS rate was most apparent in node-positive patients (73.1% vs. 65.8% for outer vs. inner hemisphere lesions, p<0.001) and in patients with primary tumors greater than 2 cm in diameter (78.2% vs. 72.3%, p=0.002). Multivariate analysis showed that tumor location was an independent predictor of DFS (hazard ratio [HR], 1.23; p=0.002) and OS (HR, 1.28; p=0.006). There were no significant differences in 5-year DFS or OS rates between patients with outer versus inner hemisphere tumors when internal mammary node irradiation was performed.

Conclusion: This study demonstrated that tumor location was an independent prognostic factor for operable breast cancer. Internal mammary node irradiation is recommended for patients with breast cancer of the inner hemisphere and positive axillary lymph nodes or large primary tumors.

No MeSH data available.


Related in: MedlinePlus